Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages

Journal of Biological Chemistry

Volumn 287, Issue 30, 2012, Pages 25139-25150

  Lohse, Stefan ^a   Brunke, Christina ^a   Derer, Stefanie ^a   Peipp, Matthias ^a   Boross, Peter ^b   Kellner, Christian ^a   Beyer, Thomas ^a   Dechant, Michael ^a   Van Der Winkel, Jan G J ^b,c   Leusen, Jeanette H W ^b   Valerius, Thomas ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c GENMAB   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITIES; EFFECTOR CELLS; EPIDERMAL GROWTH FACTOR RECEPTORS; FUNCTIONAL CHARACTERIZATION; GROWTH INHIBITION; HEAVY AND LIGHT CHAINS; HEAVY CHAIN; HIGHER EFFICIENCY; IMMUNE SYSTEMS; LIGHT CHAIN; MONOMERIC FORMS; TARGET CELLS; TUMOR CELLS; TUMOR GROWTH; TUMOR IMMUNOTHERAPY; WHOLE BLOOD; WILD TYPES;

BODY FLUIDS; CELL CULTURE; CELL DEATH; CELL PROLIFERATION; MACROPHAGES; TUMORS;

ANTIBODIES;

EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN A; RECOMBINANT ANTIBODY; RECOMBINANT IMMUNOGLOBULIN A2 ANTIBODY; UNCLASSIFIED DRUG;

ALLOTYPE; ANIMAL CELL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BINDING AFFINITY; BLOOD; CANCER CELL CULTURE; CELL KILLING; CONTROLLED STUDY; COVALENT BOND; CYTOKINE RELEASE; DRUG PROTEIN BINDING; EFFECTOR CELL; FEMALE; GROWTH INHIBITION; HEAVY CHAIN; HUMAN; HUMAN CELL; LIGHT CHAIN; MACROPHAGE ACTIVATION; MONOCYTE; NONHUMAN; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN MODIFICATION; RECEPTOR DOWN REGULATION; WILD TYPE;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, CD; CELL LINE, TUMOR; CRICETINAE; DOWN-REGULATION; HUMANS; IMMUNITY, CELLULAR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN ALLOTYPES; IMMUNOTHERAPY; MACROPHAGES; MONOCYTES; MUTATION; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, FC;

EID: 84864085474     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.353060     Document Type: Article

References (49)

1. Reichert, J. M. (2011) Antibody-based therapeutics to watch in 2011. MAbs 3, 76-99
2. Carter, P. J. (2006) Potent antibody therapeutics by design. Nat. Rev. Immunol. 6, 343-357
3. Brüggemann, M., Williams, G. T., Bindon, C. I., Clark, M. R., Walker, M. R., Jefferis, R., Waldmann, H., and Neuberger, M. S. (1987) Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J. Exp. Med. 166, 1351-1361 (Pubitemid 18051427)
4. Dechant, M., Vidarsson, G., Stockmeyer, B., Repp, R., Glennie, M. J., Gramatzki, M., van De Winkel, J. G., and Valerius, T. (2002) Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing. Blood 100, 4574-4580 (Pubitemid 35429700)
5. Ghetie, V., and Ward, E. S. (2000) Multiple roles for the major histocompatibility complex class I-related receptor FcRn. Annu. Rev. Immunol. 18, 739-766 (Pubitemid 30365396)
6. Wurm, F. M. (2004) Production of recombinant protein therapeutics in cultivated mammalian cells. Nat. Biotechnol. 22, 1393-1398
7. van der Neut Kolfschoten, M., Schuurman, J., Losen, M., Bleeker, W. K., Martínez-Martínez, P., Vermeulen, E., den Bleker, T. H., Wiegman, L., Vink, T., Aarden, L. A., De Baets, M. H., van de Winkel, J. G., Aalberse, R. C., and Parren, P. W. (2007) Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 317, 1554-1557 (Pubitemid 47417435)
8. Labrijn, A. F., Buijsse, A. O., van den Bremer, E. T., Verwilligen, A. Y., Bleeker, W. K., Thorpe, S. J., Killestein, J., Polman, C. H., Aalberse, R. C., Schuurman, J., van de Winkel, J. G., and Parren, P. W. (2009) Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat. Biotechnol. 27, 767-771
9. Schneider-Merck, T., Lammerts van Bueren, J. J., Berger, S., Rossen, K., van Berkel, P. H., Derer, S., Beyer, T., Lohse, S., Bleeker, W. K., Peipp, M., Parren, P. W., van de Winkel, J. G., Valerius, T., and Dechant, M. (2010) Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J. Immunol. 184, 512-520
10. Huls, G., Heijnen, I. A., Cuomo, E., van der Linden, J., Boel, E., van de Winkel, J. G., and Logtenberg, T. (1999) Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies. Cancer Res. 59, 5778-5784
11. Dechant, M., Beyer, T., Schneider-Merck, T., Weisner, W., Peipp, M., van de Winkel, J. G., and Valerius, T. (2007) Effector mechanisms of recombinant IgA antibodies against EGFR. J. Immunol. 179, 2936-2943
12. Lohse, S., Derer, S., Beyer, T., Klausz, K., Peipp, M., Leusen, J. H., van de Winkel, J. G., Dechant, M., and Valerius, T. (2011) Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing. J. Immunol. 186, 3770-3778
13. Macpherson, A. J., McCoy, K. D., Johansen, F. E., and Brandtzaeg, P. (2008) The immune geography of IgA induction and function. Mucosal Immunol. 1, 11-22
14. Woof, J. M., and Kerr, M. A. (2006) The function of immunoglobulin A in immunity. J. Pathol. 208, 270-282 (Pubitemid 43126119)
15. Royle, L., Roos, A., Harvey, D. J., Wormald, M. R., van Gijlswijk-Janssen, D., Redwan el-R. M., Wilson, I. A., Daha, M. R., Dwek, R. A., and Rudd, P. M. (2003) Secretory IgA N- and O-glycans provide a link between the innate and adaptive immune systems. J. Biol. Chem. 278, 20140-20153 (Pubitemid 36799209)
16. Johansen, F. E., Braathen, R., and Brandtzaeg, P. (2001) The J chain is essential for polymeric Ig receptor-mediated epithelial transport of IgA. J. Immunol. 167, 5185-5192 (Pubitemid 33009755)
17. van Egmond, M., van Garderen, E., van Spriel, A. B., Damen, C. A., van Amersfoort, E. S., van Zandbergen, G., van Hattum, J., Kuiper, J., and van de Winkel, J. G. (2000) FcαRI-positive liver Kupffer cells: Reappraisal of the function of immunoglobulin A in immunity. Nat. Med. 6, 680-685 (Pubitemid 30398792)
18. Monteiro, R. C., and Van De Winkel, J. G. (2003) IgA Fc receptors. Annu. Rev. Immunol. 21, 177-204 (Pubitemid 37174530)
19. Phalipon, A., and Corthésy, B. (2003) Novel functions of the polymeric Ig receptor: Well beyond transport of immunoglobulins. Trends Immunol. 24, 55-58 (Pubitemid 36120638)
20. Wang, A. C., and Fudenberg, H. H. (1973) IgA and evolution of immunoglobulins. J. Immunogenet. 1, 3-31
21. Tsuzukida, Y., Wang, C. C., and Putnam, F. W. (1979) Structure of the A2m(1) allotype of human IgA-a recombinant molecule. Proc. Natl. Acad. Sci. U.S.A. 76, 1104-1108 (Pubitemid 9135161)
22. Chintalacharuvu, K. R., Yu, L. J., Bhola, N., Kobayashi, K., Fernandez, C. Z., and Morrison, S. L. (2002) Cysteine residues required for the attachment of the light chain in human IgA2. J. Immunol. 169, 5072-5077 (Pubitemid 35217176)
23. Ciardiello, F., and Tortora, G. (2008) EGFR antagonists in cancer treatment. N. Engl. J. Med. 358, 1160-1174
24. Kumar, A., Petri, E. T., Halmos, B., and Boggon, T. J. (2008) Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J. Clin. Oncol. 26, 1742-1751
25. Peipp, M., Dechant, M., and Valerius, T. (2008) Effector mechanisms of therapeutic antibodies against ErbB receptors. Curr. Opin. Immunol. 20, 436-443
26. Uchida, J., Hamaguchi, Y., Oliver, J. A., Ravetch, J. V., Poe, J. C., Haas, K. M., and Tedder, T. F. (2004) The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199, 1659-1669 (Pubitemid 38821999)
27. Algars, A., Irjala, H., Vaittinen, S., Huhtinen, H., Sundström, J., Salmi, M., Ristamäki, R., Jalkanen, S. (2012) Type and location of tumor-infiltrating macrophages and lymphatic vessels predict survival of colorectal cancer patients. Int. J. Cancer 131, 864-873
28. Mantovani, A., Sozzani, S., Locati, M., Allavena, P., and Sica, A. (2002) Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23, 549-555 (Pubitemid 35223554)
29. Leidi, M., Gotti, E., Bologna, L., Miranda, E., Rimoldi, M., Sica, A., Roncalli, M., Palumbo, G. A., Introna, M., and Golay, J. (2009) M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than M1 cells in vitro. J. Immunol. 182, 4415-4422
30. Beyer, T., Lohse, S., Berger, S., Peipp, M., Valerius, T., Dechant, M. (2009) Serum-free production and purification of chimeric IgA antibodies. J. Immunol. Methods 346, 26-37
31. Furtado, P. B., Whitty, P. W., Robertson, A., Eaton, J. T., Almogren, A., Kerr, M. A., Woof, J. M., and Perkins, S. J. (2004) Solution structure determination of monomeric human IgA2 by x-ray and neutron scattering, analytical ultracentrifugation, and constrained modeling: A comparison with monomeric human IgA1. J. Mol. Biol. 338, 921-941 (Pubitemid 38542823)
32. Novak, J., Julian, B. A., Tomana, M., and Mestecky, J. (2008) IgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy. Semin. Nephrol. 28, 78-87
33. Senior, B. W., and Woof, J. M. (2005) The influences of hinge length and composition on the susceptibility of human IgA to cleavage by diverse bacterial IgA1 proteases. J. Immunol. 174, 7792-7799 (Pubitemid 40806287)
34. Oortwijn, B. D., Roos, A., Royle, L., van Gijlswijk-Janssen, D. J., Faber-Krol, M. C., Eijgenraam, J. W., Dwek, R. A., Daha, M. R., Rudd, P. M., and van Kooten, C. (2006) Differential glycosylation of polymeric and monomeric IgA: A possible role in glomerular inflammation in IgA nephropathy. J. Am. Soc. Nephrol. 17, 3529-3539 (Pubitemid 44865296)
35. Jefferis, R., and Lefranc, M. P. (2009) Human immunoglobulin allotypes. MAbs. 1, 332-338
36. Togo, S., Shimokawa, T., Fukuchi, Y., and Ra, C. (2003) Alternative splicing of myeloid IgA Fc receptor (FcαR, CD89) transcripts in inflammatory responses. FEBS Lett. 535, 205-209 (Pubitemid 36126382)
37. Pleass, R. J., Andrews, P. D., Kerr, M. A., and Woof, J. M. (1996) Alternative splicing of the human IgA Fc receptor CD89 in neutrophils and eosinophils. Biochem. J. 318, 771-777 (Pubitemid 26320939)
38. Yin, N., Peng, M., Xing, Y., and Zhang, W. (2007) Intracellular pools of FcαRI (CD89) in human neutrophils are localized in tertiary granules and secretory vesicles, and two FcαR isoforms are found in tertiary granules. J. Leukoc. Biol. 82, 551-558 (Pubitemid 47367145)
39. Otten, M. A., Leusen, J. H., Rudolph, E., van der Linden, J. A., Beelen, R. H., van de Winkel, J. G., and van Egmond, M. (2007) FcR γ-chain dependent signaling in immature neutrophils is mediated by FcαRI, but not by FcγRI. J. Immunol. 179, 2918-2924
40. Bakema, J. E., Bakker, A., de Haij, S., Honing, H., Bracke, M., Koenderman, L., Vidarsson, G., van de Winkel, J. G., and Leusen, J. H. (2008) Inside-out regulation of FcαRI (CD89) depends on PP2A. J. Immunol. 181, 4080-4088
41. Stoppacciaro, A., Melani, C., Parenza, M., Mastracchio, A., Bassi, C., Baroni, C., Parmiani, G., and Colombo, M. P. (1993) Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon γ. J. Exp. Med. 178, 151-161 (Pubitemid 23173251)
42. Di Carlo, E., Forni, G., Lollini, P., Colombo, M. P., Modesti, A., and Musiani, P. (2001) The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 97, 339-345 (Pubitemid 32060315)
43. Sica, A., Schioppa, T., Mantovani, A., and Allavena, P. (2006) Tumor-associated macrophages are a distinct M2 polarized population promoting tumor progression: Potential targets of anti-cancer therapy. Eur. J. Cancer 42, 717-727
44. Fridlender, Z. G., Sun, J., Kim, S., Kapoor, V., Cheng, G., Ling, L., Worthen, G. S., and Albelda, S. M. (2009) Polarization of tumor-associated neutrophil phenotype by TGF-β: "N1" versus "N2" TAN. Cancer Cell 16, 183-194
45. Kerkar, S. P., Goldszmid, R. S., Muranski, P., Chinnasamy, D., Yu, Z., Reger, R. N., Leonardi, A. J., Morgan, R. A., Wang, E., Marincola, F. M., Trinchieri, G., Rosenberg, S. A., and Restifo, N. P. (2011) IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J. Clin. Invest. 121, 4746-4757
46. Pander, J., Heusinkveld, M., van der Straaten, T., Jordanova, E. S., Baak- Pablo, R., Gelderblom, H., Morreau, H., van der Burg, S. H., Guchelaar, H. J., and van Hall, T. (2011) Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab. Clin. Cancer Res. 17, 5668-5673
47. Yoo, E. M., Trinh, K. R., Lim, H., Wims, L. A., and S. L. Morrison (2011) Characterization of IgA and IgM binding and internalization by surface-expressed human Fcα/μ receptor. Mol. Immunol. 48, 1818-1826
48. Maruoka, T., Nagata, T., and Kasahara, M. (2004) Identification of the rat IgA Fc receptor encoded in the leukocyte receptor complex. Immunogenetics 55, 712-716 (Pubitemid 38221671)
49. Rifai, A., Fadden, K., Morrison, S. L., and Chintalacharuvu, K. R. (2000) The N-glycans determine the differential blood clearance and hepatic uptake of human immunoglobulin (Ig)A1 and IgA2 isotypes. 191, 2171-2182